CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.


Begin main content


Last Updated: March 11, 2016
Result type: Reports
Project Number: SE0483-000
Product Line: Reimbursement Review

Generic Name: Infliximab

Brand Name: Inflectra (Subsequent Entry Biologic)

Manufacturer: Hospira HealthCare Corporation, a Pfizer Company

Therapeutic Area: Crohn’s disease and Ulcerative Colitis

Indications: Crohn’s disease and Ulcerative Colitis

Submission Type: Initial

Project Status: Complete

Date Recommendation Issued: October 25, 2016

Recommendation Type: Reimburse with clinical criteria and/or conditions